STEP: Phase IIIb study of benralizumab to step-down maintenance therapy in patients with severe eosinophilic asthma

Trial Identifier: D3250L00046
Sponsor: AstraZeneca
Start Date: February 2024
Primary Completion Date: October 2025
Study Completion Date: July 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100029
CN Beijing, CN, 100191
CN Beijing, CN, 100020
CN Chengdu, CN, 610072
CN Chengdu, CN, 610014
CN Guangzhou, CN, 510280
CN Guangzhou, CN, 510630
CN Hangzhou, CN, 310009
CN Hohhot, CN, 10050
CN Huzhou, CN, 313003
CN jinan, CN, 250014
CN Jinan, CN, 250012
CN lanzhou, CN, 730000
CN Lanzhou, CN, 730030
CN Nanjing, CN, 211100
CN Nanning, CN, 530021
CN Ningbo, CN, 315010
CN Shanghai, CN, 200080
CN Shanghai, CN, 200065
CN Shenzhen, CN, 518036
CN Shenzhen, CN, 518001
CN Shenzhen, CN, 518101
CN Shenzhen, CN, 518039
CN Shijiazhuang, CN, 054001
CN Shijiazhuang, CN, 50051
CN suzhou, CN, 215006
CN Suzhou, CN, 215004
CN Taiyuan, CN, 030001
CN Tangshan, CN, 63000
CN Wenzhou, CN, 325000
CN Wuhu, CN, 241000
CN Xi'an, CN, 710006
CN Xinxiang, CN, 453100
CN Yangzhou, CN, 225001
CN Zhangzhou, CN, 363099
CN Zhengzhou, CN, 450007